Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Frequently asked questions
What sector does Revolution Medicines, Inc (RVMD) operate in?
Revolution Medicines, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Revolution Medicines, Inc (RVMD) current stock price?
As of the latest data, Revolution Medicines, Inc stock price is $201.60, with a previous close of $205.26. Revolution Medicines, Inc lost -$3.66 in the last trading session, representing a -1.78% loss.
What is Revolution Medicines, Inc (RVMD) current market capitalization?
Revolution Medicines, Inc market cap is approximately 43.21 billion.
What is Revolution Medicines, Inc (RVMD) Earnings Per Share (EPS)?
The trailing EPS is -$8.87, and the forward EPS is -$5.48.
What is Revolution Medicines, Inc (RVMD) EBITDA?
Revolution Medicines, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -620.59 million.
Does Revolution Medicines, Inc (RVMD) pay dividends?
No. Revolution Medicines, Inc does not pay a dividend.
What is Revolution Medicines, Inc (RVMD) beta (volatility) score?
Revolution Medicines, Inc has a beta of 1.403, suggesting it is more volatile than the market.
